安罗替尼综合治疗软组织肉瘤的疗效分析

Analysis of the Efficacy of Anlotinib in the Treatment of Soft Tissue Sarcoma

摘要: 目的：探究无法完整手术切除的软组织肉瘤患者后期行安罗替尼联合传统化疗和单纯传统化疗的疗效对比。方法：1、收纳39例软组织肉瘤患者，均经手术切除后，组织病理学检测确诊，且手术无法完整切除肿瘤。23例采用安罗替尼联合化疗方案治疗，16例采用单纯化疗方案，最终对39例患者的疗效进行随访。结果：对比两组患者肿瘤复发时间的数据，并进行两组之间组间比较，安罗替尼组患者肿瘤复发时间和肺转移时间明显延长，差异有统计学意义(P < 0.05)。且在1年内软组织肉瘤患者复发率和肺转移率明显下降。结论：安罗替尼联合传统化疗治疗软组织肉瘤疗效好于单纯传统化疗治疗。

Abstract: Objective: To compare the efficacy of anlotinib combined with conventional chemotherapy and con-ventional chemotherapy alone in patients with soft tissue sarcoma that could not be removed by complete surgery. Methods: Thirty-nine patients with soft tissue sarcoma were included, all of whom were confirmed by histopathological examination after surgical resection, and the tumor could not be completely removed by surgery. Twenty-three patients were treated with anlotinib combined with chemotherapy, 16 patients were treated with chemotherapy, and 39 patients were finally followed up for efficacy. Results: The data of tumor recurrence time in the two groups were compared between the two groups. The tumor recurrence time and lung metastasis time in the anlotinib group were significantly prolonged, with statistically significant differences (P < 0.05). In addition, the recurrence rate and lung metastasis rate of soft tissue sarcoma patients decreased significantly within 1 year. Conclusion: The efficacy of anlotinib combined with conventional chemotherapy in the treatment of soft tissue sarcoma is better than that of conventional chemotherapy alone.